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Since the discovery of MeCP2, its functions have attracted the interest of generations
of molecular biologists. Its function as a transducer of DNA methylation, the major
post-biosynthetic modiﬁcation found throughout genomes, and its association with the
neurodevelopmental disease Rett syndrome highlight its central role as a transcriptional
regulator, and, at the same time, poses puzzling questions concerning its roles in physiology
and pathology.The classical model of the MeCP2 function predicts its role in gene-speciﬁc
repression through the binding of methylated DNA, via its interaction with the histone
deacetylases and co-repressor complexes. This view has been questioned and, intrigu-
ingly, new roles for MeCP2 as a splicing modulator and as a transcriptional activator have
been proposed. Recent data have demonstrated that MeCP2 is extremely abundant in
the neurons, where it reaches the level of histone H1; it is widely distributed, tracking
the methylated CpGs, and regulates repetitive elements expression. The role of MeCP2
in maintaining the global chromatin structure is further sustained by its involvement in
other biologically relevant phenomena, such as the Line-1 repetitive sequences retrotrans-
position and the pericentromeric heterochromatin clustering during cellular differentiation.
These new concepts renew the old view suggesting a role for DNAmethylation in transcrip-
tional noise reduction, pointing to a key role for MeCP2 in the modulation of the genome
architecture.
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MeCP2 AND DNA METHYLATION: IN LIMINE
In 2012, the twentieth anniversary of MeCP2 protein identiﬁca-
tion will be celebrated (Lewis et al., 1992). The impulse that this
discovery gave to research in various, often apparently unrelated
biological ﬁelds, from gene regulation to medical genetics, has
been immense. Here we cannot describe the enormous weight of
data produced, in 20 years, by an increasing number of teams.
Rather, we wish to review current research on the MeCP2 biology
starting from older scientiﬁc hypotheses.
MeCP2 was the second methyl-CpG-binding protein to be
identiﬁed, although it was the ﬁrst to be cloned. In fact, Boyes and
Bird (1991) demonstrated that the methyl-CpG-binding protein
MeCP1 can mediate the repression of transcription from densely
methylated genes. MeCP1 is able to bind various methylated
sequences “in vitro,” if at least 12 symmetrically methylated CpGs
are available. Like many important ﬁndings, MeCP2 was discov-
ered “by accident”by Boyes and Bird (1991), who were attempting
to identify the factors that bind unmethylated DNA to protect
CpG islands from DNA methylation (Clouaire and Stancheva,
2008). Rat MeCP2 had been successfully isolated through its
ability to bind methylated substrates. Then, after its puriﬁca-
tion, its cDNA had been cloned, thus enabling the knowledge
of the nucleotide sequence of the ﬁrst methyl CpG DNA gene
(Lewis et al., 1992).
MeCP2 is able to bind at a genome-wide level, with the need of a
single, methylated CpG. This weak discrimination is in agreement
with its diffuse nuclear signal in rat cells. Inmouse cells, given their
peculiar heterochromatin organization, the staining is extremely
evident in the pericentromeric heterochromatin, closely resem-
bling the distribution of major satellite DNA (Lewis et al., 1992).
Mouse satelliteDNA is enriched of methylatedCpGs, thus explain-
ing the co-localization of MeCP2 with these genomic regions.
MeCP2 was the ﬁrst methyl-binding protein to be biochemi-
cally dissected, revealing the presence of a number of functional
domains. The most noticeable domains are the methyl-binding
domain (Nan et al., 1993), responsible for binding with the methy-
lated cytosines and the transcriptional repression domain (Nan
et al., 1997), which mediates the link with the histone modiﬁca-
tions (Jones et al., 1998; Nan et al., 1998; Fuks et al., 2003) and
the co-repressors. They play a fundamental role in modulating
the functions of MeCP2, the main one being, without doubt, the
transduction of DNA methylation. These functions ﬁt with an
earlier study reporting that the loss of the X-linked methyl-CpG-
binding protein 2 (MeCP2) caused embryonic lethality in chimeric
mice (Tate et al., 1996). Taken together, these data highlighted the
role(s) of MeCP2 as a genome modulator, whose functions are
indispensable for life.
DNA methylation is present, in various degrees, from bacte-
ria to invertebrates and vertebrates. It plays a role in defending
bacterial genomes from foreign DNA invasion (Hendrich and
Tweedie, 2003). Vertebrate genomes are globally methylated,
whereas in invertebrate genomesDNAmethylation is patchy. DNA
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methylation is involved in chromatin remodeling in vertebrates,
whereas it is often located inside the genes in invertebrates, such as
in D. melanogaster (Mandrioli, 2007). Its genome-wide pattern, in
vertebrates, prompted Bird to hypothesize an association between
a global repressive effect of DNA methylation and the increase in
gene number, which is evident when switching from invertebrate
to vertebrate genomes (Bird, 1995). In fact, a major change in the
distribution of DNA methylation occurred at the invertebrate–
vertebrate boundary (Tweedie et al., 1997; Hendrich and Tweedie,
2003). Following Bird’s hypothesis, the global repressive effects of
DNA methylation may act as an additional mechanism to suppress
transcriptional noise together with the acquisition of a nuclear
envelope and the arrangement of the chromatin, which mark
the prokaryotes/eukaryotes boundary. This is clearly postulated:
“global improvements in the ability to suppress noise will permit an
increase in the maximum gene number, allowing more genes to be
tolerated” (Bird, 1995).
Hendrich and Tweedie (2003) added further substance to
this hypothesis suggesting that “to increase the ﬁdelity of DNA
methylation-mediated silencing, and to protect against extensive
mutation, there was also a coordinate increase in the number and
diversity of methyl CpG binding proteins encoded in the proto-
vertebrate genome”. Hendrich and Bird identiﬁed a family of
methyl-binding protein genes, characterized, similarly to MECP2,
by the presence of the methyl-DNA binding domain (MBD).
These proteins, called MBD1, MBD2, MBD3, and MBD4 (Hen-
drich et al., 1999) were all (except for MBD3) characterized by
their ability to bind methylated DNA. Only MBD2 and MBD3
were conserved in invertebrates: the ancestral MBD2/3 gene was
encoded by a single gene in invertebrate genomes, in contrast
to the two separate genes encoded by vertebrates (Hendrich and
Tweedie, 2003).
Thus, if a global DNA methylation has been used, by ver-
tebrate genomes, to reduce unscheduled transcription, thereby
increasing the gene number, this would similarly provide an evo-
lutionary pressure to increase the number and diversity of the
protein(s) capable of repressing transcription through the binding
of methylated DNA.
MECP2 AND RETT SYNDROME
Rett syndrome (RTT) is a sporadic post-natal progressive neu-
rodevelopmental disorder occurring with a frequency of 1/10000–
15000 live females births and is considered the second most
common cause of mental retardation in females (Rett, 1966; Hag-
berg et al., 1983). The large majority of cases (99%) are sporadic.
In 1999, Zoghbi and colleagues (Amir et al., 1999) were able to
associate loss-of-function heterozygous mutations in the MECP2
gene to classical RTT patients. The discovery of the MECP2 muta-
tions underlying RTT was a surprise because the large amount of
data, summarized above, makes the association of MECP2 to a
monogenic disease astonishing.
Besides the large number of studies on patients, the model-
ing of RTT in mice has been instrumental in order to elucidate
the molecular basis of the disease. Mouse models have also
been pivotal in the study of expression proﬁling alterations,
necessary to identify putative MeCP2 target genes. They have
helped in the elucidation of many questions of biomedical
importance: is RTT a pure neuronal disease? Is MECP2 dosage
important for the establishment of a pathogenic status? Is RTT
reversible?
Two Mecp2 null mice obtained with Cre-LoxP technology and
carrying an ubiquitous deletion, were viable but affected by severe
neurological symptoms characteristic of RTT (Chen et al., 2001;
Guy et al., 2001). The comparative analysis of knock out and brain
selective deletions of Mecp2 suggested that the function of this
gene is relevant for the central nervous system (Chen et al., 2001;
Guy et al., 2001). Moreover, the deletion of MeCP2 in selected
brain regions or neuronal sub-types revealed the presence of spe-
ciﬁc subsets of null phenotypes, allowing to ascribe to MeCP2
different neuronal-speciﬁc functions (Fyffe et al., 2008; Samaco
et al., 2009; Chao et al., 2010).
MeCP2 dosage matters: a mouse over-expressing a transgene
containing the human MECP2 locus that shows a near twofold
MeCP2expression, showed severeprogressiveneurological pheno-
types (Collins et al., 2004). The effect of MECP2 over-expression
has also been observed in humans, where a double dosage of
MECP2 causes a severe developmental delay and mental retarda-
tion (Lubs et al., 1999). Such evidence suggests that MeCP2 levels
must be ﬁne regulated in vivo and even a mild over-expression of
this gene can have a dramatic effect.
The concept of RTT as a pure neuronal disease has recently
been challenged with results implicating the involvement of
the glial cells in the pathogenesis of RTT (Ballas et al., 2009;
Maezawa et al., 2009; Zoghbi, 2009). More recently, it has been
suggested that the microglia may inﬂuence the onset and progres-
sion of RTT by releasing elevated doses of glutamate, exerting
a toxic effect on neurons in a non-cell autonomous fashion
(Maezawa and Jin, 2010). Very interestingly, null phenotypes
in mouse models can be reversed by the re-insertion of the
Mecp2 gene (Collins et al., 2004; Luikenhuis et al., 2004; Jugloff
et al., 2008), while its over-expression by twofold is deleterious
(Collins et al., 2004; Luikenhuis et al., 2004). An almost com-
plete reversibility of the null phenotypes was obtained after the
onset of the symptoms, by removing a stop cassette in the
Mecp2 gene by a Cre-mediated excision induced by tamoxifen
administration (Guy et al., 2007). These data suggest that the neu-
rological defects caused by Mecp2 mutations can potentially be
reversed.
MeCP2 AND TRANSCRIPTIONAL CONTROL
The apparent dichotomy of MeCP2 functions (genome-wide vs
gene-speciﬁc regulator) has been widely debated. Transcriptional
proﬁling studies comparing the total brains of RTT patients or
mouse models with controls have revealed only subtle differences
in gene expression dampening a role for MeCP2 as a global regu-
lator of transcription (Chadwick and Wade, 2007). A number of
reports highlightedBDNF as a bona ﬁde target of MeCP2 in rodent
systems (Chen et al., 2003;Martinowich et al., 2003). BDNF is a key
signaling molecule involved in brain development and plasticity
(Greenberg et al., 2009; Cohen-Cory et al., 2010). The mechanism
of its transcriptional regulation is, therefore, quite controversial
(Dani et al., 2005; Chang et al., 2006).
To simplify the expression analysis of a complex tissue such
as the brain, Zoghbi and colleagues (Chahrour et al., 2008;
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Ben-Shachar et al., 2009) performed microarray expression
analyses, respectively, in the hypothalamus and cerebellum of
Mecp2 nullmice and of over-expressingmice (MECP2-Tg; Collins
et al., 2004), comparing the results with wild type (WT) mice. Sur-
prisingly, both reports revealed that MeCp2 is responsible for a
subtle repression but also for an activation of many genes, and
that some of them were similarly, deregulated in both hypotha-
lamus and cerebellum of the Mecp2 null and MECP2-Tg mice
(Figures 1A,B). Furthermore, it has been conﬁrmed that MeCP2
directly binds the promoter region of the genes down-regulated
in the Mecp2 null mice and up-regulated in the MECP2-Tg mice,
while sequential ChIP assays have revealed that the promoter of
the activated genes is simultaneously associated with both MeCP2
and the known transcriptional activator CREB1 (Figure 1B).
These data suggest that MeCP2 regulates the expression of a wide
range of genes in different brain sub-regions and point to a role
for MeCP2 as a modulator of transcription that can both acti-
vate or repress target genes (Chahrour et al., 2008; Ben-Shachar
et al., 2009). Moreover, the transcriptional alterations observed
in the MECP2-Tg mice have conﬁrmed the deleterious effect of
the Mecp2 over-expression reported by different research groups
(Collins et al., 2004; Luikenhuis et al., 2004).
A category of genes investigated as a putative target of MeCP2
is that of imprinted genes, whose expression is regulated by dif-
ferential methylation. For example, several studies have focused
on Ube3A, a gene imprinted in the brain (Rougeulle et al., 1998)
and associatedwith Prader–Willi andAngelman syndromes. How-
ever, to date, the expression alteration of this gene in Mecp2-null
mice has not been clearly understood (Guy et al., 2011). Another
imprinted region bound by MeCP2 in the mouse brain includes
the Dlx5 and Dlx6 genes, located in an imprinted gene cluster
on chromosome 6. Its transcription is nearly two times greater
in brains of Mecp2-null mice compared to those of WT mice
and, in the same model, the chromatin loop in the Dlx5/6 locus
enriched with methylated H3K9 present in the WT brain is absent
(Figure 1C; Horike et al., 2005).
MeCP2 deﬁciency affects also Line-1 (L1) transcription and
retrotransposition: these are, in fact, increased in the mouse
brains from null mice and in the neural precursor cells obtained
from iPSC and postmortem brains from RTT patients (Muotri
et al., 2010).
The L1 elements are retrotransposons representing 20% of
mammalian genomes that may induce genomic alterations, such
as insertions and deletions (Kazazian, 1998; Perepelitsa-Belancio
and Deininger, 2003; Han and Boeke, 2004). Moreover, a massive
somatic L1 insertion can occur in adult brain tissues, a phe-
nomenon that can alter the expression of the neuronal genes
(Muotri et al., 2005; Coufal et al., 2009). These data were con-
ﬁrmed by another report which revealed an increased transcript
level of the L1-elements, intracisternal A particles, and tandem
repetitive units of the mouse major satellite in the Mecp2 null
brains compared to WT mice (Skene et al., 2010).
MeCP2 AND ITS COFACTORS
As already described regarding the interaction between MeCP2
and CREB, proteins with which it interacts may modify the roles
of MeCP2 (Figures 1A,B).
FIGURE 1 | (A) An example of MeCP2 mediated transcriptional repression:
the methyl-DNA binding domain (MBD) binds methylated CpG sites and
recruits histone deacetylases and co-repressors (Sin3A), inducing chromatin
compaction and gene silencing (Nan et al., 1998; Chen et al., 2003; Klose
and Bird, 2003). (B) MeCP2 is able to activate the transcription of some
genes in hypothalamus, by binding unmethylated promoters and recruiting
CREB1 and, potentially, co-activators (Chahrour et al., 2008). (C) MeCP2 is
responsible for the silencing of Dlx5/6 imprinted locus by inducing the
formation of a silent higher order chromatin loop (Horike et al., 2005).
The ﬁrst potential connection between MeCP2 and chromatin
came from the ﬁnding that MeCP2 copuriﬁes with the Sin3-
histone deacetylase complex (Jones et al., 1998; Nan et al., 1998).
Based on this observation, most current models depict MeCP2
as a transcriptional repressor that facilitates repression through
local histone deacetylation mediated by the passive recruitment
of histone deacetylases (Bird and Wolffe, 1999). Klose and Bird
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(2004) demonstrated that MeCP2 is a non-obligatory component
of the Sin3a co-repressor complex. Moreover, MeCP2 exists as a
monomeric protein in solution and does not stably associate with
other proteins.
In addition to Sin3a, several other factors have been reported to
bind mammalian MeCP2, including DNMT1, CoREST, Suv39H1,
and c-SKI (Nan et al., 1998; Kokura et al., 2001; Lunyak et al.,
2002; Kimura and Shiota, 2003) although the contribution of these
factors to MeCP2-mediated repression is not known.
MeCP2 also interacts with ATRX, a SWI/SNF family ATPase.
MeCP2 recruits ATRX to the heterochromatic foci, but this local-
ization is disrupted in Mecp2 null neurons. ATRX localization is
disrupted also by the A140V MECP2 mutation found in XLMR
patients (Orrico et al., 2000; Nan et al., 2007). Unexpectedly,
the complex MeCP2/ATRX with cohesin preferentially binds the
unmethylated allele of the H19 gene. This may depend on the
association of MeCP2 with this large complex or on regions of
non-speciﬁc afﬁnity present in MeCP2 (Guy et al., 2011).
A binding of MeCP2 to the trithorax-related protein Brahma
(Brm) has also been reported. Brm and MeCP2 assemble on the
methylated genes involved in cancer and on the FMR1 gene in
fragile X syndrome (Harikrishnan et al., 2005). Therefore, this
interaction is still controversial (Hu et al., 2006).
A physical interaction between the heterochromatin protein
1 (HP1) and MeCP2 has been demonstrated during the myo-
genic differentiation. In particular, this interaction leads to the
re-localization of HP1γ to the heterochromatin, which corre-
lates with the presence of MeCP2 (Agarwal et al., 2007). There
is no doubt that works aimed at the dissection of the inter-
actions of MeCP2 with other partners, in particular using the
novel sequencing-based techniques (Skene et al., 2010), may open
the way to a better understanding of the roles and functions
of MeCP2.
MeCP2: GLOBAL REGULATORY ROLES
DNA methylation affects the nuclear architecture, as measured
by the gene position alterations in the chromosome territories
(Matarazzo et al., 2007). A direct role of MeCP2 in nuclear archi-
tecture rearrangements has not been reported. Rather, the role(s)
of MeCP2 in genome-wide phenomena, such as pericentromeric
heterochromatin clustering, has recently been analyzed (Brero
et al., 2005; Agarwal et al., 2011; Singleton et al., 2011). During the
myogenic differentiation of mouse C2C12 cells, the pericentric
heterochromatin domains undergo a reorganization and cluster
into a smaller number of larger chromocenters (Figure 2). These
events are accompanied by an increase in the methylation of major
satelliteDNAand the accumulation of MeCP2 andMBD2proteins
in the nuclei of terminally differentiatedmuscle cells. Interestingly,
the over-expression of MeCP2 and MBD2 in C2C12 myoblasts
in the absence of differentiation also induces an aggregation of
the chromocenters, indicating that these proteins may be directly
involved in the reorganization of heterochromatin architecture.
Moreover, studies in Mecp2 null mouse neurons have revealed
signiﬁcant differences in the number and size of the nucleoli and
chromocenters compared to WT animals (Singleton et al., 2011).
Already in 2002, it was shown that mice carrying a Mecp2 trun-
cating mutation have a higher level of hyperacetylated histone H3
FIGURE 2 | Clustering of pericentromeric heterochromatin domains
(chromocenters, blue spots) during myogenic differentiation of C2C12
myoblasts to myotubes (Brero et al., 2005).
compared with WT mice, emphasizing a generally altered chro-
matin architecture (Shahbazian et al., 2002). The development of
techniques permitting genome-wide epigenomic studies are con-
tributing to the assessment of MeCP2 functions in the chromatin
architecture and genome organization.
In 2007, LaSalle and colleagues reported, by ChIP-chip analysis
on a neuroblastoma cell line, that more than half of the MeCP2
binding sites are intergenic and that only a small number of them
reside in the CpG islands. Moreover, among binding sites located
in the CpG islands, many of them are associated with actively
transcribed genes, supporting the viewof amore complex function
of MeCP2 (Yasui et al., 2007).
Different approaches, reagents, and technologies led, some
years later, to the re-establishment of MECP2 as a protein with
a global regulatory role (Skene et al., 2010). The utilization of
next generation sequencing approaches in the neuronal nuclei
from the mature mouse brain has revealed that the abundance
of MeCP2 is similar to the number of nucleosomes (Skene et al.,
2010). Moreover, as previously reported (Shahbazian et al., 2002),
in the absence of Mecp2, the H3 acetylation levels are increased,
while the H1 levels are doubled, pointing a role for MeCP2 in the
global chromatin organization.
Furthermore, an analysis of binding sites around known reg-
ulated genes, such as BDNF and Dlx5/6, transcriptionally active
in this cellular system, has revealed a MeCP2 binding across the
entire locus, except for the CpG island regions, suggesting that
these active promoters are unable to bind MeCP2 due to its
hypomethylation state. Moreover, high-throughput data suggest
that the MeCP2 binding in vivo tracks the density of methyl-CpG
in the genome (Skene et al., 2010). These latter data have revealed
that MeCP2 is one of the most abundant nuclear proteins in the
mature neurons suggesting a crucial role for MeCP2 in neurons as
a regulator of the entire genome.
The described data suggest that, in addition to the role of
MeCP2 as a gene-speciﬁc transcriptional regulator, mediated by
the association with speciﬁc cofactors, the global chromatin-
binding function of MeCP2 is crucial for global chromatin
dynamics especially during brain maturation. MeCP2 may thus be
seen as amultifunctional and structural organizing factor. Further-
more, the interaction of MeCP2 with most regions of the genome,
such as the intergenic DNA and repetitive elements, should con-
tribute to keep the rate of somatic mutation and transcriptional
noise in the brain low and allows to hypothesize further pathogenic
roles for MeCP2 in RTT. This evidence recalls the concept we pre-
viously described, focusing on the role of MeCP2 as a key player
in genome architecture and regulation.
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